Browse Category

NYSE:BDX News 16 October 2025

Shocking CFO Departure Sends BDX Stock Tumbling — But Growth Remains Strong

Shocking CFO Departure Sends BDX Stock Tumbling — But Growth Remains Strong

Leadership Change and Growth: BD’s CFO Chris DelOrefice surprised the market by resigning in mid-Octoberprnewswire.com. According to the official release, DelOrefice is pursuing an outside opportunity, and Roque will cover the CFO role through the transition. Polen emphasized DelOrefice’s contributions to BD’s strategic overhaul and said Roque — a 20-year finance veteran at BD — is “well positioned” to keep executing the company’s plansprnewswire.comreuters.com. The leadership news coincided with a positive earnings update: BD reported that Q4 sales hit $5.89 billion (a +8.3% increase)finimize.com and full-year revenue about $21.8 billion. On a constant-currency, organic basis growth was more modest (~4% for Q4),
16 October 2025

Stock Market Today

AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026
AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.
Go toTop